Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18 to 24 years or 50 to 85 years who are available for the entire duration of the study, able to be contacted by phone, and able to complete all study procedures, including completion of an electronic diary (e-diary).~* Men and women who are able to have children, must use a reliable method of birth control for the duration of the study.~Exclusion Criteria:~* Any major illness that would substantially increase the risk associated with participation in the study, or interfere with the evaluation of the study objectives - this is determined by the local physician.~* Donation of 250 mL or more of blood within the last 3 months.~* Condition associated with prolonged bleeding time, including subjects taking anticoagulant medication or antiplatelet therapy.~* Any contraindication to vaccination or vaccine components.~* Immunocompromised persons and subjects who receive treatment with immunosuppressive therapy.~* Previous administration of S. aureus vaccination.~* Receipt of blood products or immunoglobulins within 12 months prior to study~* Participation in another trial (not including observational trials) within the last 30 days.~* Study site personnel or immediate family members (first-degree relatives).~* Women who are pregnant (as determined by urine pregnancy test) or breast-feeding.~* Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care.~* For subjects aged 65 years or older, a Mini-Mental State Examination (MMSE) score of \<=21.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): SA3Ag in both stage 1 and stage 2
- 2 (Type: EXPERIMENTAL): SA3Ag in stage 1 followed by placebo in stage 2.
- 3 (Type: PLACEBO_COMPARATOR): Placebo in both stage 1 and stage 2
- 4 (Type: EXPERIMENTAL): SA3Ag in stage 1 and no vaccine in stage 2.
- 5 (Type: PLACEBO_COMPARATOR): Placebo in stage 1 and no vaccine in stage 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).